At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
Eculizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single-Arm, Multicenter Trial to Determine Safety and Efficacy of Eculizumab in the Prevention of Antibody Mediated Rejection (AMR) in Sensitized Recipients of a Kidney Transplant From a Deceased Donor.
In Brief
A Phase 2 clinical trial evaluating Eculizumab for Stage V Chronic Kidney Disease. Completed, enrolled 80 participants across 15 sites in 6 countries.
Detailed Summary
Primary Objective: To evaluate the safety and potential efficacy of eculizumab to prevent AMR in sensitized recipients of deceased donor kidney transplants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage V Chronic Kidney Disease
CountriesAustralia, France, Italy, Spain, Sweden, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2012
Enrollment StartAug 2012
Primary CompletionJun 2015
Study CompletionMay 2017
TodayJul 2026
First PostedMar 30, 2012
Enrollment StartAug 29, 2012
Primary CompletionJun 11, 2015
Study CompletionMay 24, 2017
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 14.3 years ago
Interventions
Eculizumabdrug